Sanofi Loses Preliminary Injunction Bid Against Novo’s Levemir Promotional Materials
This article was originally published in The Pink Sheet Daily
New Jersey federal court finds that Novo Nordisk’s claims regarding the insulin injection’s duration of effect and predictability are not literally false.
You may also be interested in...
Planned second quarter launch would be nearly one year after FDA approval.
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.
A Phase III trial will compare 40 mg/day glatiramer to the 20 mg/day approved dose.